Fig. 1

Multivariate analysis of death and dependence 6 months after TIA. (Reprinted with permission from Daffertshofer M, Mielke O, Pullwitt A, Felsenstein M, Hennerici M. Transient ischemic attacks are more than “ministrokes.” Stroke. 2004; 35:2453-8.)

Fig. 2

Time to first event included in composite end point (nonfatal stroke, TIA, nonfatal myocardial infarction, and major bleeding complications) in patients with ischemic stroke treated with aspirin 25 mg plus dipyridamole 200 mg twice daily (early initiation group) or aspirin 100 mg (late initiation group) within 24 h of symptom onset for the first 7 days followed by aspirin 25 mg plus dipyridamole 200 mg twice daily for up to 90 days. (Hazard ratio [HR, 0.73, 95% confidence interval [CI] 0.44 to 1.19; P = .20). (Republished with permission from Dengler R, Diener HC, Schwartz A, Grond M, Schumacher H, Machnig T, Eschenfelder CC, Leonard J, Weissenborn K, Kastrup A, Haberl R; EARLY Investigators. Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): a randomised, open-label, blinded-endpoint trial. Lancet Neurol. 2010;9(2):159-66.)